Parkin gene therapy for α-synucleinopathy: A rat model of Parkinson's disease

Parkinsonism and Related Disorders

Volumn 12, Issue SUPPL. 2, 2006, Pages

  Mochizuki, Hideki ^a,b   Yamada, Masanori ^a   Mizuno, Yoshikuni ^a,b  

^a JUNTENDO UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

synuclein; AAV vector; Gene therapy; Parkin; Parkinson's disease

Indexed keywords

ADENOVIRUS VECTOR; ALPHA SYNUCLEIN; PARKIN;

ALPHA SYNUCLEINOPATHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DISEASE; CELL LOSS; CONTROLLED STUDY; DISEASE MODEL; DOPAMINERGIC NERVE CELL; GENE OVEREXPRESSION; MOTOR DYSFUNCTION; NERVE CELL DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 33749065368     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2006.05.014     Document Type: Article

References (13)

1. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998) 605-608
2. Shimura H., Hattori N., Kubo S., Mizuno Y., Asakawa S., Minoshima S., et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25 (2000) 302-305
3. Choi P., Golts N., Snyder H., Chong M., Petrucelli L., Hardy J., et al. Co-association of parkin and alpha-synuclein. NeuroReport 12 (2001) 2839-2843
4. Imai Y., Soda M., Inoue H., Hattori N., Mizuno Y., and Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of parkin. Cell 105 (2001) 891-902
5. Darios F., Corti O., Lucking C.B., Hampe C., Muriel M.P., Abbas N., et al. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet 12 (2003) 517-526
6. Kim S.J., Sung J.Y., Um J.W., Hattori N., Mizuno Y., Tanaka K., et al. Parkin cleaves intracellular alpha-synuclein inclusions via the activation of calpain. J Biol Chem 278 (2003) 41890-41899
7. Petrucelli L., O'Farrell C., Lockhart P.J., Baptista M., Kehoe K., Vink L., et al. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36 (2002) 1007-1019
8. Yang Y., Nishimura I., Imai Y., Takahashi R., and Lu B. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 37 (2003) 911-924
9. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T.E., Muzyczka N., et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 22 (2002) 2780-2791
10. Klein R.L., King M.A., Hamby M.E., and Meyer E.M. Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. Hum Gene Ther 13 (2002) 605-612
11. Lo Bianco C., Ridet J.L., Schneider B.L., Deglon N., and Aebischer P. Alpha-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci USA 99 (2002) 10813-10818
12. Yamada M., Iwatubo T., Mizuno Y., and Mochizuki H. Overexpression of α-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of α-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J Neurochem 91 (2004) 451-461
13. Yamada M., Mizuno Y., and Mochizuki H. Parkin gene therapy for α-synucleinopathy: a rat model of Parkinson's disease. Hum Gene Ther 16 (2005) 262-270